Reported Saturday, Akero Therapeutics Presented Data Highlighting The Efficacy And Safety Of EFX In Patients With MASH At EASL Congress
Reported Saturday, Akero Therapeutics Presented Data Highlighting The Efficacy And Safety Of EFX In Patients With MASH At EASL Congress
A late-breaking oral presentation will feature 96-week data from HARMONY, a Phase 2b study evaluating the efficacy and safety of EFX in patients with metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2–F3). The study met its primary endpoint of ≥1-stage improvement in fibrosis with no worsening of MASH after 24 weeks of treatment for both the 50 mg EFX (41%, p<0.05) and 28 mg EFX (39%, p<0.05) dose groups, compared to 20% for the placebo group. At Week 96, response rates for this endpoint increased to 75% (p<0.001) for 50 mg EFX and 46% (p=0.07) for 28 mg EFX, vs 24% for placebo.
一份最新的口头报告将呈现HARMONY研究96周的数据，该研究评估了EFX对代谢紊乱相关的脂肪肝（MASH）和纤维化2-3期（F2-F3）患者的疗效和安全性。该研究在50 mg EFX（41％，p
The study also met additional histology endpoints at week 96. Notably 36% (p<0.01) and 31% (p<0.01) of patients treated with 50 mg EFX and 28 mg EFX, respectively, had a 2-stage improvement in fibrosis without worsening of MASH, more than 10-fold the placebo rate of 3%.
该研究还在96周时达到了其他组织学终点。值得注意的是，分别接受50 mg EFX和28 mg EFX治疗的患者有36％（p